Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.

Eli Lilly reported net income of $4.41 billion, or $4.88 per share, on revenue of $13.53 billion. Analysts had expected profit of $4.52 billion, or $4.99 per share, on $13.56 billion in revenue, per Visible Alpha.

After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11.

Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3.53 billion and $1.91 billion, respectively, below expectations of $3.65 billion and $2.04 billion.

Eli Lilly said it expects 2025 revenue between $58.0 to $61.0 billion, with EPS from $22.05 to $23.55, and adjusted EPS of $22.50 to $24.00. Those ranges are largely in line with or above expectations.

The results come one day after rival Novo Nordisk (NVO), the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report.

Eli Lilly shares were up more than 2% immediately following the report. They entered the day up about 20% over the last 12 months. By contrast, Novo Nordisk shares are down about 25% in the past year.